Navigation Links
NeurogesX to Present at Roth 2008 OC Growth Stock Conference
Date:2/19/2008

SAN MATEO, Calif., Feb. 19 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present at the Roth Capital Partners 20th Annual OC Growth Stock Conference in Laguna Niguel, CA on February 20, 2008. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the break out session.

Event: Roth Capital 20th Annual OC Growth Stock Conference

Date: Wednesday, February 20, 2008

Time: 2:00 p.m. Pacific Time

Place: Ritz Carlton, Laguna Niguel, CA (Salon 3)

An audio Web cast of the Company's presentation will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX-4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX The Ruth Group

Stephen Ghiglieri Investors / Media

(650) 358-3310 Stephanie Carrington / Jason Rando

sghiglieri@neurogesx.com (646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
2. NeurogesX Closes $25 Million Private Placement
3. NeurogesX, Inc. Announces $25 Million Private Placement
4. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX Expands Senior Management Team
7. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
8. NeurogesX Appoints New Director to the Board
9. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... ... announced orders for advanced VPG+ 800 Volume Pattern Generators from two major Asian ... tomorrow’s demand for production of advanced photomasks as well as a solution for ...
(Date:8/22/2017)... ... August 22, 2017 , ... ... built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox has adapted their ... pipeline to be provide scientists with easy to understand reports, extended indel analysis, ...
(Date:8/21/2017)... ... August 21, 2017 , ... ... its extensive experience with Health Economics and Outcomes Research (HEOR) and ‘big data’ ... In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on ...
(Date:8/17/2017)... ... August 17, 2017 , ... CNA Finance Chief ... provided a research update on Aytu Bioscience and cited promising increases in the ... Soulstring, prescription rates for Natesto® have more than doubled since March of this ...
Breaking Biology Technology:
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):